Evolent Health resumed with an Outperform at Leerink

Leerink analyst David Larsen resumed coverage of Evolent Health with an Outperform rating and $35 price target, telling investors in a research note that he remains positive on shares following the close of the New Century Health acquisition. Larsen says he is “more confident” in Evolent’s growth prospects given the company’s greater presence in Medicare Advantage, Oncology and Cardiology, and says the deal makes strategic sense and will help enable Evolent to serve as a “conduit” between providers and payors to drive lower costs and improved outcomes.
https://thefly.com/landingPageNews.php?id=2800329